• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Combined Administration of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine and Conjugated Serogroup C Vaccine Indicated for Prevention of Meningococcal Disease Is Safe and Immunogenic
【24h】

Combined Administration of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine and Conjugated Serogroup C Vaccine Indicated for Prevention of Meningococcal Disease Is Safe and Immunogenic

机译：B型脑膜炎球菌血清外膜囊泡疫苗和C型血清共轭疫苗联合预防脑膜炎球菌疾病的安全性和免疫原性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

MenBvac and Menjugate are safe and efficacious vaccines. The purpose of this study was to evaluate safety and immunogenicity of the combination (MenB/C) of the lyophilized active components of the conjugated group C vaccine Menjugate when reconstituted with the full liquid group B outer membrane vesicle vaccine MenBvac compared to MenBvac and Menjugate given separately. At 6-week intervals, healthy adults were given one dose of MenB/C followed by two doses of MenBvac (MenB/C group), three doses of MenBvac (MenB group), or one dose of Menjugate and two doses of placebo (MenC group). Injection site reactions were frequent in all groups. However, most reactions were short lasting and mild or moderate in intensity, and the vaccines were found to be well tolerated, with no vaccine-related serious adverse events. MenB/C was immunogenic with regard to both serogroup B and C meningococci. Both the serum bactericidal assay and the enzyme-linked immunosorbent assay analyses showed that the immune responses of the combination vaccine were similar to the immune responses of its separate components MenBvac and Menjugate for both serogroup B and C. In conclusion, the combined MenB/C vaccine is safe and immunogenic. The two vaccines do not interact negatively with each other and can easily be administered in the same syringe. The induced immune responses suggest that the combined vaccine is likely to confer protection against systemic group B disease caused by the vaccine strain as well as against group C meningococcal disease.
机译：MenBvac和Menjugate是安全有效的疫苗。这项研究的目的是评估与全液B组外膜囊泡疫苗MenBvac相比，与给定的MenBvac和Menjugate相比，结合的C组疫苗Menjugate的冻干活性成分组合（MenB / C）的安全性和免疫原性分别。每隔6周向健康成人服用一剂MenB / C，然后再服用两剂MenBvac（MenB / C组），三剂MenBvac（MenB组）或一剂Menjugate和两剂安慰剂（MenC）组）。在所有组中注射部位反应都很频繁。但是，大多数反应持续时间短，强度轻或中等，发现疫苗耐受性好，没有与疫苗相关的严重不良事件。 MenB / C对B和C型脑膜炎双球菌均具有免疫原性。血清杀菌试验和酶联免疫吸附试验均表明，联合疫苗的免疫反应与其单独的组分MenBvac和Menjugate对B和C血清群的免疫反应相似。总之，组合的MenB / C疫苗安全且具有免疫原性。两种疫苗不会互相产生负面影响，可以轻松地在同一注射器中注射。诱导的免疫应答表明，组合疫苗可能赋予针对疫苗株引起的系统性B组疾病以及C组脑膜炎球菌疾病的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号